These differences in sample size (i.e. especially right-censored non-manifest carriers and non-carriers), community-based recruitment and event measures (i.e. age of PD diagnosis) may explain why our observed cumulative incidence of LRRK2 G2019S PD was lower compared to previously published estimates.9,65. This evidence concerns the gene LRRK2 and Parkinson disease.